Commerzbank Analysts Give Fresenius Medical Care AG & Co. KGaA (FME) a €80.00 Price Target

Fresenius Medical Care AG & Co. KGaA (ETR:FME) received a €80.00 ($93.02) price objective from equities researchers at Commerzbank in a research note issued to investors on Wednesday. The brokerage presently has a “neutral” rating on the stock. Commerzbank’s price objective suggests a potential upside of 15.21% from the company’s previous close.

Several other equities research analysts also recently weighed in on the company. JPMorgan Chase & Co. set a €97.90 ($113.84) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a report on Wednesday, August 29th. Barclays set a €87.20 ($101.40) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a “neutral” rating in a research note on Friday, September 28th. Sanford C. Bernstein set a €107.00 ($124.42) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research note on Tuesday, August 7th. Goldman Sachs Group set a €98.00 ($113.95) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research note on Friday, August 24th. Finally, UBS Group set a €86.00 ($100.00) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a “neutral” rating in a research note on Monday, August 6th. Nine research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of €95.27 ($110.78).

FME stock opened at €69.44 ($80.74) on Wednesday. Fresenius Medical Care AG & Co. KGaA has a twelve month low of €75.53 ($87.83) and a twelve month high of €93.82 ($109.09).

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the U.S.

Read More: Book Value Of Equity Per Share – BVPS Explained

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply